Sector News

Nonadherence costs pharma $600B-plus in annual sales: study

November 22, 2016
Life sciences

Pharma knows nonadherence costs it major money. But just how much money?

$637 billion in potential sales annually, with $250 billion in the U.S. alone last year, according to a new study. Coauthors HealthPrize and Capgemini repeated their research from 2012, when they found $564 billion in lost revenue globally and $188 billion in the U.S. That means the global tally has increased by 13%, and 33% in the U.S.

The attention on adherence more often focuses on the added medical costs to the healthcare system—estimated at $300 billion annually—and the cost in health outcomes for patients. Pharma companies have more recently joined the conversation with partnerships and programs that include adherence aims; efforts from Verily and Sanofi and IBM and Novo Nordisk have recently made news.

However, that’s a newer mindset. Until recently, pharma companies didn’t pay much attention to adherence because they didn’t have to, said Tom Kottler, CEO of HealthPrize Technologies, in an interview with FiercePharma.

“When large primary care drugs ruled the market and that’s where pharma made all their money, they would just get doctors to write more scripts,” he said. “… Pharma also used to make a lot of money just by raising prices, but I think that gravy train is coming to an end, considering what’s happening in the marketplace today.”

He added, “And I think pharma should want it to come to an end. They need to have less pressure on them from the marketplace in general and we think focusing on adherence is a way to do that.”

The benefits of working on adherence could be a boon for pharma, he said. Revenue grows, healthcare system costs decrease, patient health outcomes are better, and as a bonus—pharma’s reputation gets shinier.

But there’s a downside to pushing adherence that may be holding some pharma companies back. That’s the perception of drug “pushing,” with some critics suggesting that adherence programs are being used as marketing tools to get patients to fill and refill prescriptions.

While Kottler’s HealthPrize is an adherence software service company that could benefit from pharma attention, he is far from alone in advocating adherence. The proliferation of tech and pharma deals—along with the earlier mentions, Qualcomm has deals with both Novartis and Boehringer-Ingelheim—often have adherence goals baked in.

Research, too, has long pointed to the problems of noncomplaince. One of the most recent studies from IMS Institute focused on the costs of “suboptimal” drug adherence in a study on diabetes and found that among the U.S. Medicare population alone, $4 billion of spending was associated with poor Type 2 diabetes adherence and related complications. And government groups like the FDA and the National Institutes of Health have pushed calls to action to improve adherence.

With outcome-based healthcare on the rise, another group, payers are also likely to get involved in the adherence discussion.

By Beth Snyder Bulik

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend